Results of recent studies indicate that loss of FoxP1 activity promotes solid tumor proliferation, e.g. in endometrial cancer, prostate cancer, renal cell carcinoma, and breast cancer, suggesting a tumor-suppressive role in these malignancies [16, 33]. This evidence concerns the gene FOXP1 and prostate carcinoma.